CYMODIQ Trademark

Trademark Overview

On Wednesday, December 30, 2015, a trademark application was filed for CYMODIQ with the United States Patent and Trademark Office. The USPTO has given the CYMODIQ trademark a serial number of 86861586. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 2, 2019. This trademark is owned by Pfizer Inc.. The CYMODIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
cymodiq

General Information

Serial Number86861586
Word MarkCYMODIQ
Filing DateWednesday, December 30, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 2, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 6, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 8, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, December 2, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 2, 2019ABANDONMENT - NO USE STATEMENT FILED
Saturday, April 13, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 12, 2019EXTENSION 5 GRANTED
Monday, April 8, 2019EXTENSION 5 FILED
Monday, April 8, 2019TEAS EXTENSION RECEIVED
Saturday, October 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 11, 2018EXTENSION 4 GRANTED
Thursday, October 11, 2018EXTENSION 4 FILED
Thursday, October 11, 2018TEAS EXTENSION RECEIVED
Thursday, June 21, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 20, 2018EXTENSION 3 GRANTED
Tuesday, May 1, 2018EXTENSION 3 FILED
Tuesday, June 19, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 1, 2018ASSIGNED TO EXAMINER
Friday, May 4, 2018NOTICE OF REVIVAL - E-MAILED
Friday, May 4, 2018EXTENSION RECEIVED WITH TEAS PETITION
Friday, May 4, 2018PETITION TO REVIVE-GRANTED
Friday, May 4, 2018TEAS PETITION TO REVIVE RECEIVED
Thursday, October 5, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 3, 2017EXTENSION 2 GRANTED
Tuesday, October 3, 2017EXTENSION 2 FILED
Tuesday, October 3, 2017TEAS EXTENSION RECEIVED
Friday, March 24, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 22, 2017EXTENSION 1 GRANTED
Wednesday, March 22, 2017EXTENSION 1 FILED
Wednesday, March 22, 2017TEAS EXTENSION RECEIVED
Tuesday, November 1, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 6, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 6, 2016PUBLISHED FOR OPPOSITION
Wednesday, August 17, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 2, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, August 2, 2016ASSIGNED TO LIE
Thursday, July 21, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 10, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, March 10, 2016LETTER OF SUSPENSION E-MAILED
Thursday, March 10, 2016SUSPENSION LETTER WRITTEN
Tuesday, March 8, 2016ASSIGNED TO EXAMINER
Friday, January 8, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, January 2, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

cymodiq preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases